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A B S T R A C T
We report a 55-year-old female patient with refractory vasospastic angina and bronchial asthma treated
successfully with corticosteroids. She was diagnosed with vasospastic angina by coronary angiography
and the acetylcholine provocation test. Even after administration of oral vasodilators (benidipine,
diltiazem, nicorandil, isosorbide mononitrate) she had recurrent chest pain with ST elevation. She had a
history of bronchial asthma, so we added 30 mg/day of oral prednisolone. Her symptoms disappeared
completely upon treatment. This case report suggests that corticosteroids are a therapeutic choice for
patients with refractory vasospastic angina, especially for those with bronchial asthma.
<Learning objective: We report a 55-year-old female patient with refractory vasospastic angina and
bronchial asthma. Even after administration of oral vasodilators, she had recurrent chest pain with ST
elevation. She had a history of bronchial asthma, so we added 30 mg/day of oral prednisolone. Her
symptoms disappeared completely upon treatment. This case report suggests that corticosteroids are a
therapeutic choice for patients with refractory vasospastic angina, especially for those with bronchial
asthma.>
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Vasospastic angina can cause not only angina pectoris but also
myocardial infarction, and even sudden cardiac death with fatal
arrhythmia [1–4]. Usually, it is controlled satisfactorily with oral
vasodilators such as calcium antagonists and nitrates. However,
some patients with vasospastic angina are resistant to conven-
tional oral vasodilators. Those patients are recognized as having
‘‘refractory vasospastic angina’’ (RVA).
There are several treatments for RVA. Some case reports have
shown the effectiveness of corticosteroids, especially in patients
with allergic disease [3,4]. However, there is a paucity of data
regarding the effectiveness of corticosteroids for vasospastic
angina, as well as for the relationship between inﬂammation or
allergic reactions and coronary vasospasm.
Here we describe a case of RVA with bronchial asthma treated
successfully with corticosteroids in addition to oral vasodilators.* Corresponding author at: Department of Cardiology, Ashikaga Red Cross
Hospital, 284-1 Yobe-cho, Ashikaga, Tochigi, Japan. Tel.: +81 284 21 0121;
fax: +81 284 21 6810.
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A 55-year-old female patient was referred to our hospital with a
chief complaint of chest pain of 2-week duration. She complained
of an increasing frequency of chest pain, especially in the morning
and at rest. These ﬁndings were consistent with a diagnosis of
worsening angina. She had a history of bronchial asthma, but no
risk factors for coronary heart disease. She arrived at our hospital
with no medication.
Physical examination ﬁndings were almost normal. Electrocardi-
ography (ECG) and chest radiography did not reveal abnormal
ﬁndings. Hematology showed a white blood cell count of 4100/mL
(neutrophils, 44.9%; lymphocytes, 42.1%; monocytes, 6.6%; eosino-
phils, 5.9%; and basophils, 0.5%), a hemoglobin level of 13.4 g/dL, and
a platelet count of 17.1  104/mL. Serum samples showed a negative
level of troponin-T (0.006 ng/mL), slight elevation of the level of brain
natriuretic peptide (BNP; 22.4 pg/mL), and a normal level of
C-reactive protein (CRP; 0.15 mg/dL). Transthoracic echocardiogra-
phy showed a normal size and contractility of the left ventricle. She
was admitted to our hospital with a diagnosis of unstable angina.
Diagnostic coronary angiography revealed no signiﬁcant
atherosclerotic stenosis in the coronary arteries. The acetylcho-
line provocation test was undertaken to investigate coronarys reserved.
Fig. 1.
Coronary angiography and the acetylcholine provocation test. Angiogram of the right coronary artery using 6-Fr Judkins right catheter (left anterior oblique and
cranial view): (a) control angiogram, (b) angiogram after acetylcholine provocation (Ach), and (c) angiogram after intracoronary infusion of isosorbide dinitrate
(ISDN).
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the right ventricle via the right femoral vein in case of bradycardia.
There was no clear evidence of severe coronary vasospasm in the
left coronary artery with intracoronary infusion of acetylcholine
(25, 50, and 100 mg). However, the right coronary artery was
almost totally occluded upon provocation with acetylcholine
(50 mg; Fig. 1b) with chest pain. ECG revealed ST elevation in leads
II, III, and aVF, as well as ST depression in leads I, aVL, and V1–V4
(Fig. 2a). After intracoronary infusion of isosorbide dinitrate,
coronary spasm was reversed (Fig. 1c) and the electrocar-
diographic changes were normalized (Fig. 2b). She was diagnosed
with vasospastic angina.
In addition to continuous intravenous administration of
isosorbide dinitrate, we started oral vasodilators (8 mg/day of
benidipine, 15 mg/day of nicorandil), but she had recurrent chest
pain with ST elevation in leads II, III, and aVF in the morning (Fig. 3).
Usually, her symptoms were relieved with sublingual nitroglycerin
or a temporary bolus intravenous infusion of isosorbide dinitrate.
We added 200 mg/day of diltiazem and 40 mg/day of isosorbide
mononitrate. However, she had recurrent chest pain with ST
elevation every day (especially early in the morning). Because she
had RVA with a history of bronchial asthma, we added 30 mg/day
of oral prednisolone. Simultaneously, we started inhalation of
200 mg/day of ﬂuticasone propionate, because of her history of
bronchial asthma.
Her symptoms disappeared completely, and intravenous
administration of isosorbide dinitrate was discontinued
(Fig. 3). Prednisolone was decremented by 5 mg/day every 3 days.
She was discharged from hospital with vasodilators (8 mg/day of
benidipine, 15 mg/day of nicorandil, 200 mg/day of diltiazem,
40 mg/day of isosorbide mononitrate) and 10 mg/day of prednis-
olone. At the time of hospital discharge, hematology showed a
white blood cell count of 3300/mL (neutrophils, 71.6%; lympho-
cytes, 19.3%; monocytes 7.3%; eosinophils 1.8%; and basophils
0.0%), a hemoglobin level of 13.1 g/dL, a platelet count of
12.5  104/mL, a BNP level of 16.9 pg/mL, and a CRP level of
<0.10 mg/dL.
After discharge from hospital, prednisolone was decremented
by 1 mg/day every 2 weeks. Finally, we prescribed 4 mg/day of
prednisolone as maintenance therapy. The patient remained free of
anginal symptoms during 12-month follow-up.
Discussion
Vasospastic angina is more common in Japan compared with
Western countries [5]. The mechanism of action and pathophysiologyof coronary spasm is not clear, but endothelial dysfunction and
alternation of autonomic nervous tone are considered to be major
factors [6]. Vasospastic angina is usually well controlled with oral
vasodilators such as calcium antagonists and nitrates, and it is rare for
patients with vasospastic angina to be refractory to conventional
vasodilators.
We had prescribed 8 mg/day of benidipine, 15 mg/day of
nicorandil, 200 mg/day of diltiazem, and 40 mg/day of isosorbide
mononitrate, but our patient continued to have recurrent chest
pain with appreciable ST elevation (Fig. 3). Therefore, additional
therapy was needed to control angina and to prevent adverse
events such as myocardial infarction or sudden cardiac death.
There are invasive and non-invasive choices for the treatment
of RVA. b1 receptor agonists, vitamin E, and endothelin antagonists
are non-invasive methods. Current guidelines state that use of
corticosteroids is only a class-IIb indication for the treatment of
vasospastic angina [7]. However, some case reports have
demonstrated the effectiveness of corticosteroids for the treatment
of RVA, especially in patients with allergic disease (e.g. bronchial
asthma, chronic thyroiditis, Raynaud phenomenon, eosinophilia)
[3,4]. Our case report is, in general, consistent with those reports.
Other case reports reported focal inﬁltration of inﬂammatory cells
in the coronary arteries of patients with vasospastic angina [8].
Therefore, local inﬂammation of the coronary artery may be
associated with coronary vasospasm. The mechanism of action
explaining the effectiveness of corticosteroids for coronary
vasospasm is not clear, but case reports as well as the present
study suggest that anti-inﬂammatory effects may contribute to
control vasospastic angina. In our case, although there was no clear
evidence of eosinophilia or elevation of inﬂammatory markers,
blood tests showed that the number of eosinophils and levels of
CRP decreased after oral administration of prednisolone. Takagi
et al. [3] reported that corticosteroids were effective for patients
with RVA with active and non-active bronchial asthma. Bronchial
asthma was not active in our patient, but corticosteroids can
suppress inﬂammation and hyper-reactivity in the coronary
arteries, which can lead to vasospastic angina [3,4]. The initial
dose of oral prednisolone for the treatment of RVA is controversial,
because there are no guidelines for the volume used for such
therapy. Case reports have suggested that the initial dose of oral
prednisolone should be 20–40 mg/day [3,4]. In accordance to those
case reports, we started with 30 mg/day of oral prednisolone as an
initial dose of 0.5 mg/kg/day because her body weight was
approximately 60 kg.
Conversely, it has been reported that corticosteroids are not
effective for the treatment of atherosclerotic coronary artery
Fig. 2.
Electrocardiography. (a) Electrocardiogram revealing ST elevation in leads II, III, and aVF as well as ST depression in leads I, aVL, and V1–V4 after acetylcholine
provocation. (b) Electrocardiographic changes are normalized after intracoronary infusion of isosorbide dinitrate.
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Fig. 3.
Time-course of treatment. She had recurrent chest pain with ST elevation after oral administration of vasodilators. Finally, her symptoms disappeared upon
treatment with 30 mg/day of oral prednisolone and inhalation of 200 mg/day of ﬂuticasone propionate.
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methylprednisolone did not improve the short-term outcomes of
patients with unstable angina, whereas this therapy signiﬁcantly
decreased serum levels of CRP. Roberts et al. [10] reported the
deleterious effects of methylprednisolone in patients with myocar-
dial infarction. In addition, long-term administration of corticoste-
roids can lead to adverse side effects such as hypertension,
corticosteroid-induced diabetes mellitus, congestive heart failure,
susceptibility to infection, osteoporosis, and gastroduodenal ulcers.
Therefore, the use of corticosteroids should be considered in
carefully selected patients with RVA with allergic disease.
Stent implantation is also a treatment for refractory focal
vasospastic angina [2]. However, stenting does not work in
patients with diffuse or multivessel coronary spasm [2]. In our
case, stent implantation was not an option because coronary
vasospasm occurred diffusely in the distal segment of the right
coronary artery (Fig. 1c). In addition, some studies reported that
implantation of drug-eluting stents was associated with vascular
endothelial dysfunction and coronary vasospasm [6]. Furthermore,
there are the problems of restenosis and continuous antiplatelet
therapy to prevent stent thrombosis after stent implantation [2].
Therefore, stent implantation should be carried out in carefully
selected patients with RVA.
Brachytherapy and sympathectomy are also therapeutic
choices for RVA [1], but are invasive. Our patient had a history
of bronchial asthma, so corticosteroids in addition to conventional
oral vasodilators were the most appropriate and least invasive
therapy for RVA.
In summary, our case report suggests that corticosteroids are a
therapeutic choice for patients with RVA, especially for those with
bronchial asthma. Further investigation involving a larger cohort is
necessary to evaluate the effect of corticosteroids for the treatment
of RVA.Conﬂict of interest
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